Status: Recruiting
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Participants needed: 180
Trial details
Phase: Phase 2Age: 18-83Biological sex: AllType: InterventionalSponsor: Tectonic TherapeuticUpdated: Mar 27, 2026Locations: 86
Eligibility criteria
Is a male or female of non-childbearing potential between the ages of 18 and 83... [+5]
Diagnosis of PH in World Health Organization (WHO) Group 1, WHO Group 3, WHO Gro... [+16]